Immunotech Biopharm Ltd (HK:6978) has released an update.
Immunotech Biopharm Ltd has announced a reduction in its loss before tax by 22% for the first half of 2024 compared to the same period in 2023, despite an increase in research and development expenses. The company, a leader in cellular immunotherapy in China, highlighted its core product EAL’s long-standing clinical application in cancer treatment. Overall, the firm experienced a significant dip in net assets, and its loss per share has decreased from the previous year.
For further insights into HK:6978 stock, check out TipRanks’ Stock Analysis page.
